BackSummary
Allogene Therapeutics announced a proposed underwritten public offering of its common stock and suspended its existing at-the-market offering program.
Key takeaways
- The company announced a proposed underwritten public offering of its common stock on April 13, 2026.
- The company suspended its existing at-the-market offering program under the Sales Agreement with TD Securities (U.S.A.) LLC.
- No sales will occur under the suspended program until a new prospectus or prospectus supplement is filed with the SEC.
- The announcement does not constitute an offer to sell securities, which requires a proper prospectus.